baber/WOPTO huggingface dataset:
Patent NZ-508057-A (NZ)
Title: 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
Inventor: LOWE JOHN ADAMS
IPC: C09K23/16
Filed: 1999-05-07
Abstract: Compounds of formula (I) are described, pharmaceutical compositions of the compounds and their uses as NOS inhibitors, wherein; n and m  in the bridging rings are independently 1, 2 or 3, and a carbon in one of the bridging rings may be substituted by a heteroatom selected from O, S and N, with the proviso that a bridghead carbon can only be substituted by a nitrogen, R1 and R2 are independently selected from C1-6alkyl, which may be linear, branched or cyclic or contain both linear and cyclic branched and cyclic moieties, wherein each or R1 and R2 may be optionally substituted, or R1 and R2 form, together with the nitrogen to which they are attached, a piperazine, azetidine, piperidine or pyrrolidine ring or an azabicyclic ring containing from 6 to 14 ring members. The piperazine, azetidine, piperidine or pyrrolidine rings may be optionally substituted
Patent NZ-509848-A (NZ)
Title: Inverter for injecting sinusoidal currents into an alternating current network
Inventor: WOBBEN ALOYS
IPC: H02M7/48
Filed: 1999-09-07
Abstract: To feed sine wave current into the AC network the circuit between each respective voltage rail and common for each respective phase includes switches T1, T3, T5 (T2, T4, T6) and diodes D1, D3, D5 (D2, D4, D6) connected in series between the voltage rail and common, with a current tapping between the respective switches and diodes, load current for the respective phases being drawn from the current tap during the respective positive and negative halves of the AC cycle. A second switch, respectively S1, S3, S5 (S2, S4, S6) and a decoupling inductor L1, L3, L5 (L2, L4, L6) is connected in series with the current tap and the load. Switches S1, S3, S5 remain closed during production of the positive part of the network current, and switches S2, S4, S6 remains closed during production of the negative part of the network current, for further providing load current to the load.
Patent NZ-512533-A (NZ)
Title: A combination of IBAT inhibitor and nicotinic acid derivative to treat hypercholesterolemia, hyperlipidemic or atherosclerotic conditions
Inventor: KELLER BRADLEY T
IPC: A61K31/77
Filed: 1999-12-17
Abstract: Described are combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. The combinations disclosed include an ileal bile acid transport inhibitor combined with a nicotinic acid derivative.
Patent NZ-516880-A (NZ)
Title: Hay conditioning apparatus
Inventor: MACKIE PETER GILBERT
IPC: A01D82/02
Filed: 2000-09-15
Abstract: A hay conditioning apparatus (20) includes a first roller (22) which is rotatably mounted in a fixed mounting and a second counter-rotating (compression) roller (24) which is rotatably mounted in connection with a moveable mounting (26). The compression roller (24) is in rolling contact with the first roller (22) and is adapted to receive pre-cut hay therebetween for conditioning. The moveable mounting (26) allows the second roller (24) to be displaced relative to the first roller (22) as the hay passes between the rollers (22, 24) and also includes a hydraulic cylinder (32) for applying a compression force to the compression roller (24). As the pre-cut hay passes between the rollers (22, 24), it is subjected to a predetermined compression force sufficient to substantially flatten any green nodes on the hay and thereby accelerate drying of the hay
Patent NZ-518182-A (NZ)
Title: Formulations for parenteral use of estramustine phosphate, a basic amino acid and human albumin for use in anti-cancer therapy
Inventor: MUGGETTI LORENA
IPC: A61K47/18
Filed: 2000-09-13
Abstract: Described are pharmaceutical formulations, which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a basic amino acid. The formulations can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulations also enable the estramustine phosphate to be administered with no side effects at the site of injection.
Patent NZ-518300-A (NZ)
Title: Novel compounds
Inventor: BRODIN THOMAS
IPC: A61P35/04
Filed: 2000-10-26
Abstract: An isolated antibody having specific for a target structure displayed on the surface of human gastrointestinal epithelial tumour cells, with the binding domain complementarity determining region (CDR) sequences in the light chain comprising amino acids 23-33 (CDR1), 49- 55 (CDR2), 88-98 (CDR3) of SEQ ID NO:2, and the binding domain CDR of the heavy chain comprising amino acids 158- 162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of SEQ ID NO:2.
Patent NZ-520342-A (NZ)
Title: 1,3-Disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
Inventor: SEILER MAX PETER
IPC: A61P25/16
Filed: 2001-01-26
Abstract: Compounds of formula (I) that have high affinity as a2 adrenoceptors and are useful as pharmaceuticals for the treatment of any state responsive to a2 adrenoceptor antagonists, and their preparations are disclosed, wherein: R0, R1, R2 and A are as defined in the specification.
Patent NZ-521415-A (NZ)
Title: Cartridge shell where one end of shell is tapered to be wedge like, for radial compression of shell upon detonation
Inventor: TOTA EDWARD
IPC: F42B3/00
Filed: 2001-02-22
Abstract: A cartridge shell 10 comprises a main body 12 defining a volume 14 for holding energetic material. The main body 12 has a first end 16 for location adjacent a toe 48 of a hole 46 and a second end 18 directed to the collar 50 of hole 46. The second end 18 is tapered to reduce in transverse area away from the first end to form a point or wedge-like member 20
Patent NZ-529087-A (NZ)
Title: A system and method for providing an insurance product
Inventor: MONK SIMON
IPC: G06Q30/06
Filed: 2003-10-22
Abstract: A method of providing an insurance product via a computing system (3) that comprises the steps of:- (a) Issuing an insurance product to a subscriber (7); and (b) Allowing the subscriber (7) to access the computing system (3) through a network (4), so as to vary at least one term of the issued insurance product.
Patent NZ-531098-A (NZ)
Title: Tank assembly for all terrain vehicle with main tank and removably connected auxiliary tank, with underside recess in main tank to accommodate pump
Inventor: SMITH WARWICK BRUCE
Filed: 2002-06-11
Abstract: A tank such as a straddle tank for farm / agricultural vehicle has a main tank section 11 which in use extends laterally of a vehicle and two arm sections 12 which extends longitudinally of a vehicle. The tank has a cavity 14 in the underside of the main tank section 11 to accommodate a pump assembly, and each arm section 12 has a distal end which is typically located at a level lower than the main tank section to provide a lower centre of gravity, and therefore aids the stability of the vehicle.
Patent NZ-531869-A (NZ)
Title: Himbacine analogues as thrombin receptor antagonists
Inventor: CHACKALAMANNIL SAMUEL
IPC: A61P35/00
Filed: 2002-10-16
Abstract: Disclosed is a thrombin receptor antagonist of structural formula (I) wherein the substituents are as defined in the specification. Compounds of the type disclosed are useful for the treatment of thrombotic, inflammatory, artherosclerotic or fibroproliferative disorders.
Patent NZ-533970-A (NZ)
Title: Process for the preparation of the 7alpha-methylsteroid, 21-hydroxy-19-norpregn-4, 6-dien-3-one
Inventor: STOELWINDER J
IPC: C07J7/00
Filed: 2003-01-14
Abstract: Described is a process for the preparation of 7á-methyl hydroxy steroids of the Formula I: Formula I wherein R1 is hydrogen, methyl or C=CH R2 is (CH2)nOH, wherein n is 0, 1 or 2 by a copper mediated 1,6-conjugate addition of a Grignard reagent CH3MgX,X being a halogen, to the 4,6- unsaturated 3-ketosteroid of formula II: Formula II wherein R1 and R2 are as previously defined, comprising protecting the hydroxy group of the steroid of Formula II with a trialkylsilyl group, followed by treating the hydroxy protected steroid with the Grignard reagent. The process is useful for the production of pharmacologically interesting steroids.
Patent NZ-534046-A (NZ)
Title: 4-(piperidyl-and pyrrolidyl-alkyl-ureido) -quinolines as urotensin II receptor antagonists
Inventor: AISSAOUI HAMED
IPC: C07D401/12
Filed: 2002-12-02
Abstract: Compounds of the general formula 1 are described. Py represents pyridin-4-yI mono-substituted in position 2 with -NR2R3; pyridin 4-yl disubstituted in position 2 with -NR2R3 and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl- quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8- methyl-5,6, 7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3- b)pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO2NR2-; aryl-SO2NR2-; arylalkyl- SO2NR2-; lower alkyl-CONR2-; aryl-CONR2-; arylalkyl-CONR2-; lower alkyl-NR3CONR2-; aryl-NR3CONR2-; arylalkyl-NR3CONR2-; aryl-CO-; arylalkyl CO-; lower alkyl-NR2CO-; arylalkyl-NR2CO-; or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent. Y represents -C(R4)(R5)(CH2)m- or -(CH2)mC(R4)(R5)-; Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen, hydroxyl, carboxyl, aryl-CONR2-, lower alkyl-NR2CO-, aryl-NR2CO- or arylalkyl-NR2CO-; n represents the numbers 0 or 1; m represents the numbers 1 or 2; R1 represents hydrogen or lower alkyl; R2 and R3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R2 and R3 are attached to the same nitrogen atom, R2 and R3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring; R4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R4 and R5 are attached as ring atoms; R5 represents hydrogen, methyl, or forms together with R4 with a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R4 and R5 are attached as ring atoms. Use of the compounds is disclosed to be for preparation of a medicament for treatment of disorders associated with a dysregulation of urotensin II. Also for the treatment of disorders associated with vascular or myocardial ischemia such as diabetes, dementia and asthma.
Patent NZ-537498-A (NZ)
Title: Storing and quantifying nucleic acid administered to a solid carrier
Inventor: DE ROOIJ ESTHER REGINA
IPC: C12Q1/70
Filed: 2003-07-03
Abstract: A method for quantifying a nucleic acid of interest in at least one blood sample, comprising: - administering said sample to a solid carrier capable of at least in part absorbing said sample, resulting in at least one spot; - drying said carrier; - excising at least one spot from said solid carrier, said at least one spot comprising at least 250 microIitres of sample; - administering said at least one spot to a chaotropic nucleic acid isolation lysis buffer; so that nucleic acid is extracted from said carrier; - further purifying the nucleic acid present in said lysis buffer; - performing a nucleic acid amplification step; and - quantifying said nucleic acid of interest.
Patent NZ-538971-A (NZ)
Title: Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease
Inventor: KIM BONGCHEOL
IPC: A23L1/30
Filed: 2003-08-12
Abstract: Disclosed is the use of a crude extract or a non-polar solvent soluble extract of hardy kiwifruit for the preparation of a composition for treating, alleviating or preventing allergic disease selected from the group consisting of anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contagious dermatitis, urticaria, insect allergies, food allergies and drug allergies.
Patent NZ-542180-A (NZ)
Title: MtHP promoter element
Inventor: WANG ZENGYU
IPC: C12N15/82
Filed: 2004-04-02
Abstract: Disclosed is an isolated nucleic acid sequence comprising a MtHP promoter, the promoter comprising the nucleic acid sequence of SEQ ID NO:1 or a fragment thereof having promoter activity. Also disclosed is a transformer containing the sequence and a plant transformed with said vector.
Patent NZ-542653-A (NZ)
Title: Pharmaceutical composition as solid dosage form and method for manufacturing thereof
Inventor: LOMRYD HAKAN
IPC: A61K38/095
Filed: 2004-04-30
Abstract: Disclosed is a pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The method involves the mixing of desmopressin acetate and an excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a disaccharide with an average particle size in the range from 70 to 100 micrometre. The method provides an improved production of solid dosage forms of desmopressin.
Patent NZ-545291-A (NZ)
Title: A pet door assembly
Filed: 2006-02-13
Abstract: A pet door assembly is disclosed that includes a support structure that defines an access opening through which a pet can pass. A connecting arrangement is positioned on the support structure to permit the support structure to be connected to at least one connector able to be fastened to an inwardly facing surface of a closure frame. A self-closing door is mounted on the support structure to be displaceable between a closed position in which the door closes the access opening and an open position.
Patent NZ-546367-A (NZ)
Title: Methanesulphonate salt of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionate to be administered orally
Inventor: BRAUNS ULRICH
IPC: A61K47/12
Filed: 2003-03-03
Abstract: Disclosed is a pharmaceutical composition for oral administration comprising the methanesulphonate salt of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)phenylamino]-methyl}-1-methyl-1 H-benzimidazole-5-carbonyl)-pyridin-2-ylamino]-propionate (formula (I)) and one or more pharmaceutically acceptable organic acids with a water solubility of > 1 g / 250 ml at 20 deg C, with the proviso that the composition does not comprise: a substantially spherical core material which consists of or contains said one or more pharmaceutically acceptable organic acids and an active substance layer containing binder and optionally separating agent which encloses the core material.
Patent NZ-548036-A (NZ)
Title: Effluent pond crust breaker using muliple rods that rotate around a horizontal axis
Inventor: ROBINSON GARRY NOEL
Filed: 2006-06-19
Abstract: An apparatus (1) and method for breaking up a crust layer on an effluent pond is disclosed. The apparatus (1) is supported substantially above the surface of the pond, by a frame (3) and flotation barrels (2), to act directly on the surface. The apparatus includes a number of rods spaced along a horizontal shaft to form an 'X' shape (4). The rods are brought into contact with the crust, by rotating the shaft, thus breaking it up and dissipating the layer.
Patent NZ-551986-A (NZ)
Title: Ultrasound contrast agent dosage formulation
Inventor: WALOVITCH RICHARD
Filed: 2004-06-04
Abstract: Disclosed is a dosage formulation providing enhanced ultrasound contrast images comprising microspheres comprising a biocompatible synthetic polymer and having incorporated therein a perfluorocarbon gas that is a gas at body temperature, wherein the microspheres are porous spheres with a honeycombed structure or sponge-like structure, wherein the dosage formulation comprises a dose of microspheres effective to provide enhanced ultrasound images for more than five minutes in the ventricular chambers or for more than one minute in the myocardium, when the microspheres are administered intravenously, and wherein the dose ranges from 0.5 to 4 mg microspheres/kg body weight.
Patent NZ-555118-A (NZ)
Title: Defective influenza virus particles incapable of producing functional polymerase
Inventor: DE WIT EMMIE
IPC: C12N7/04
Filed: 2005-11-08
Abstract: The disclosure generally relates to the field of influenza virus and vaccination against flu. The disclosure provides a method for obtaining a conditionally defective influenza virus particle including the step of transfecting a suitable cell with one or more gene constructs derived by internally deleting a nucleic acid encoding an influenza polymerase whereby said gene constructs are incapable of producing a functional polymerase but do not hinder packaging of gene segments into the viral particles. Further provided are virus particles obtained by such method, pharmaceutical compositions containing particles, and the use of such particles for the manufacture of a pharmaceutical composition directed at generating immunological protection against influenza.
Patent NZ-564250-A (NZ)
Title: Clothes iron with means for inducing orbital oscillatory motion into the sole plate
Inventor: AKHTER PERVEZ
IPC: D06F75/08
Filed: 2006-06-08
Abstract: A clothes iron comprises a body (2) and a sole plate (3). The body (2) is supported on the sole plate (3) by means of laterally resilient springs (4). The springs permit sideways movement of the sole plate (3) relative to the body (2). A motor (8) has a shaft (9) that carries an eccentric portion (10) which is received within a socket provided in the upper face of the sole plate. Thus, operation of the motor will cause the sole plate to execute orbital oscillatory motion relative to the body, in the plane of the face of the sole plate.
Patent NZ-564346-A (NZ)
Title: Utility cabinet tree
Inventor: WIN SPENCER GEORGE
Filed: 2006-06-27
Abstract: A tree shaped rack 4 for a utility cabinet or chamber 1, the tree 4 comprising a) a trunk member including b) resilient branch members extending transversely from the trunk member for engaging with and supporting at least one electrical component between branch members, the electrical component being one or more selected from: i) a cable ii) a fuse; iii) a relay, iv)a connector, and v) a switch; and c) securing formations for securing the tree shaped rack 4 to a utility cabinet or chamber 1 at a least one end of the tree shaped rack 4.
Patent NZ-565418-A (NZ)
Title: Methodology for 3D scene reconstruction from 2D image sequences
IPC: G06T13/00
Filed: 2008-01-25
Abstract: A system for the reconstruction of a 3-dimensional (3D) scene comprises image capturing means arranged to capture a plurality of 2-dimensional (2D) images of the scene; image selection means arranged to differentiate between a first subset of the images and a second subset of the images; and processing means arranged to generate a model of the 3D scene from the first subset of images, and further arranged to refine the model using the second subset. A method of scene reconstruction comprises obtaining a plurality of images of a scene representing at least two perspective views of the scene; generating a model of the scene using a first subset of the images; calculating the perspectives of each the image in the first subset using the images of the first subset; and refining the model using the calculated perspectives and a second subset of the images, wherein the second subset includes at least one image not in the first subset
Patent NZ-569651-A (NZ)
Title: Hydraulic machine, in particular hydraulic motor, and metering device comprising such a motor
Inventor: DARBOIS MATTHIEU
IPC: F04B9/10
Filed: 2006-12-07
Abstract: A hydraulic machine, in particular hydraulic motor, comprising a casing (2) with a body (3) and a cover (4); a separation means (M) which can make a reciprocating movement and defines two chambers (5, 6); hydraulic switching means (C) comprising a distribution member (D); a compartment (13) in the body of the casing connected to a pressurized-liquid inlet (14), and initiating means (15) comprising a pusher (A) connected to the separation means, these initiating means being able, at the end of the stroke, to cause a sudden change in the position of the switching means, under the action of an elastic means (E), in order to reverse the stroke. The distribution member (D) comprises a distribution slide valve (16) applied against a flat plate (17) which is fixed relative to the body of the casing, the slide valve being able to slide in a fluid-type manner, without a seal, against the plate (17), which has orifices connected respectively to the chambers (5, 6) of the casing and to a liquid outlet orifice (18), the slide valve (16) being intended, depending on its position, to close some of the orifices or to place them in communication with the fluid inlet or the outlet.
Patent NZ-576065-A (NZ)
Title: Method for treating cancer harboring egfr mutations
Inventor: SOLCA FLAVIO
IPC: A61P35/00
Filed: 2007-09-14
Abstract: Provided is the use of an irreversible EGFR inhibitor BIBW 2992 for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harbouring a mutation of the EGFR gene in the tumour, and wherein the cancer shows resistance or acquired resistance to treatment with gefitinib and/or erlotinib. The inhibitor can be combined with other further chemotherapeutic agents.
Patent NZ-577013-A (NZ)
Title: Cheese products containing galacto-oligosaccharides and having reduced lactose levels
Inventor: SILVER RICHARD STUART
IPC: A01J25/00
Filed: 2009-05-15
Abstract: Disclosed is a method for producing a galacto-oligosaccharide-containing cheese product comprising: a) treating a lactose-containing dairy substrate with lactase enzyme(s) having trans-galactosylation activity and hydrolytic activities for a time and at a temperature effective for converting at least 20 percent of the lactose present in the dairy substrate to galacto-oligosaccharides; and b) processing the treated dairy substrate to provide a cheese product having at least about 0.5 grams galacto-oligosaccharides per serving, and less than about 1 gram lactose per serving, wherein the cheese product is selected from the group consisting of cottage cheese, process cheese, and cream cheese, wherein the lactose-containing dairy substrate has at least about 7 percent lactose for process cheese and cream cheese and at least about 4 percent lactose for cottage cheese, and wherein the serving size for process cheese and cream cheese is 1 ounce and the serving size for cottage cheese is 4 ounces.
Patent NZ-577824-A (NZ)
Title: Methods of identifying neoplasm-specific antibodies and uses thereof
Inventor: VOLLMERS HEINZ PETER
IPC: C12N5/09
Filed: 2004-11-12
Abstract: Provided is a purified or isolated antibody or a functional fragment thereof comprising a heavy and light chain variable regions with at least 80% identity to the specified amino acid sequences, and wherein the antibody or functional fragment thereof specifically binds to an adenocarcinoma of the colon, a diffuse-type stomach carcinoma, an adenocarcinoma of the pancreas, or an adenocarcinoma of the lung. Further provided are corresponding nucleic acids coding for the antibody, expression vectors and cells comprising the vectors. The compositions can be used for diagnosis or medical treatment of proliferative disorders. (62) Divided Out of 547260